Conditions: ATIII Deficiency
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 45
Healthy volunteers: no

Brief summary:
The purpose of this study is to test whether the administration of ATIII during the intra-operative period results in improved anticoagulation for cardiopulmonary bypass (CPB) and an attenuation of the activation of the coagulation cascade, as represented by a decrease in fibrin degradation products. The investigators believe this benefit would extend into the post-operative period resulting in a decreased incidence of thrombosis generation, as represented by a decrease in fibrin degradation products in the ICU period.

Detailed description:
If Preoperative ATIII functional assay level is less than 70% patients would be enrolled and randomized to either Placebo (normal saline) or ATIII.

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Anti-thrombin III intervention 2: Placebo
Intervention descriptions: intervention 1: Intraoperatively- (correcting to 100%) according to the following formula:

Units required = ((100%- baseline ATIII level\*%) X body weight)/1.4

* expressed as a % normal level based on functional ATIII assay intervention 2: Normal saline placebo

Protocol document: